Results 61 to 70 of about 6,071 (199)

Management of Infants Treated for Respiratory Viral Infections: A Finnish Retrospective Register‐Based Study

Health Science Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background and Aims Viral respiratory tract infections are common in all age groups, and they are responsible for a vast number of health care visits every year. Furthermore, the incidence of respiratory infections is the highest in children.
Sallamaria Länsisalo, Paula Heikkilä, Sauli Palmu   +2 more
wiley   +1 more source

Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies

, 2014
Marie Linder,1 Camilla Byström,1 Helle Kieler,1 Gunnar Bergman,2 Ann Haerskjold3,4 1Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden; 2Stockholm-Uppsala Department of Pediatric Cardiology ...
Linder M, Kieler H, Bergman G, Byström C, Haerskjold A   +4 more
core  

Palivizumab em contexto domiciliário [PDF]

, 2012
O Departamento de Pediatria, nomeadamente a UCIENP, através do Projeto de Apoio Domiciliário ao Recém-Nascido internado na UCIEN, formou em 2009, uma equipa multidisciplinar de apoio domiciliário, em parceria com a Fundação do Gil, procurando contribuir ...
Amaral, J, Lopez, M, Costa, M, Cunha, A
core  

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey

The Turkish Journal of Pediatrics, 2012
The main aim of this study was to evaluate the cost-effectiveness of respiratory syncytial virus (RSV) prophylaxis with palivizumab in Turkey, by comparing hospitalization rates and costs as well as results of risk analyses in preterm infants who ...
Mehmet Yekta Oncel, Banu Mutlu, Sumru Kavurt, Ahmet Yağmur Baş, Nihal Demirel, Mesut Akyol, Omer Erdeve, Uğur Dilmen   +7 more
doaj  

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source

A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation

BMC Research Notes, 2012
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in children globally. Predisposing conditions for the development of serious RSV disease include preterm infants and those with cardiopulmonary ...
Turti Tatyana V, Baibarina Elena N, Degtiareva Elena A, Keshishyan Elena S, Lobzin Yurii V, Namazova-Вaranova Leyla S, Prodeus Andrey P, Gudkov Konstantin M, Kruglova Anna I, Schulz Gregory A, Notario Gerard F   +10 more
doaj   +1 more source

Palivizumab Administration Decreases Recurrent Wheeze

, 2014
Children who have been infected with Respiratory Syncytial Virus have a higher incidence of wheeze-associated clinic visits and hospitalizations compared to children without previous RSV exposure. The purpose of this study is to determine if palivizumab,
Daniels, Shelly
core  

The clinical significance of palivi-zumab in the prevention of severe respiratory infections in newborn infants [PDF]

Саратовский научно-медицинский журнал, 2016
Palivizumab is known as the world's first drug with proven efficacy for passive immunization of severe infections of lower respiratory tract in preterm infants.
Bykova Е.М., Gavrilova E.S., Borisova А.А., Pazgalyova N.V., Panina O.S., Chernenkov Yu.V.   +5 more
doaj  

Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy

BMC Pediatrics, 2009
Background Bronchiolitis is a distressing, potentially life-threatening respiratory condition that affects infants. We evaluated the incidence and risk factors of hospitalization for broncholitis in preterm infants (i.e., a gestational age of
Mucchino Eleonora, Benincori Nicoletta, Mantovani Jessica, Pezzotti Patrizio, Di Lallo Domenico   +4 more
doaj   +1 more source

Structural elucidation of the interactions between F glycoprotein and palivizumab.

, 2019
(a) Predicted structure of the RSV-A postfusion F glycoprotein (PDB: 3RRT) bound to palivizumab Fab fragment (PBD: 2HWZ). Pink dots, antigenic site II (amino acid residues 258–275); upper panel, side view; lower panel, top view.
Rabih Andary (6387881), Mireille Lteif Khoury (6387875), Reiko Saito (155351), Ghassan Dbaibo (340842), Aia Assaf-Casals (6387869), Soha Ghanem (3090774), Nadia Soudani (6387866), Hadi Abou-El-Hassan (6387860), Elie Massaad (6387863), Maria Karam (6387878), Hassan Zaraket (194276), Rouba Shaker (6387872)   +11 more
core   +1 more source